EBI-907, a novel BRAFV600E inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile

Cancer Biology and Therapy

Volumn 17, Issue 2, 2016, Pages 199-207

  Zhang, Jiayin ^a   Lu, Biao ^b   Liu, Dong ^a   Shen, Ru ^a   Yan, Yinfa ^a   Yang, Liuqing ^a   Zhang, Minsheng ^a   Zhang, Lei ^b   Cao, Guoqing ^b   Cao, Hu ^b   Fu, Beibei ^b   Gong, Aishen ^b   Sun, Qiming ^b   Wan, Hong ^b   Zhang, Lianshan ^c   Tao, Weikang ^b   Cao, Jingsong ^a  

^a Eternity Bioscience Inc   (United States)

^b Hengrui Pharmaceutical Ltd   (China)

^c Jiangsu Hengrui Medicine   (China)

Author keywords

BRAF; BRAFV600E; EBI 907; inhibitors; kinase; MAPK; RAF

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; EBI 907; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; UNCLASSIFIED DRUG; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; EBI-907; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; IC50; MOUSE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COLON TUMOR; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; MUTATION; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; ISOQUINOLINES; MICE; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZOLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961198322     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1139231     Document Type: Article

References (23)

1. J.A.McCubrey, L.S.Steelman, W.H.Chappell, S.L.Abrams, E.W.Wong, F.Chang, B.Lehmann, D.M.Terrian, M.Milella, A.Tafuri, et al. Roles of the MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773:1263–84; PMID:17126426; http://dx.doi.org/10.1016/j.bbamcr.2006.10.001
2. J.Downward Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3:11–22; PMID:12509763; http://dx.doi.org/10.1038/nrc969
3. E.R.Cantwell-Dorris, J.J.O'Leary, O.M.Sheils. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 2011; 10:385–94; PMID:21388974; http://dx.doi.org/10.1158/1535-7163.MCT-10-0799
4. S.Dietrich, H.Glimm, M.Andrulis, C.von Kalle, A.D.Ho, T.Zenz. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 2012; 366:2038–40; PMID:22621641; http://dx.doi.org/10.1056/NEJMc1202124
5. H.Davies, G.R.Bignell, C.Cox, P.Stephens, S.Edkins, S.Clegg, J.Teague, H.Woffendin, M.J.Garnett, W.Bottomley, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949–54; PMID:12068308; http://dx.doi.org/10.1038/nature00766
6. R.B.Corcoran, H.Ebi, A.B.Turke, E.M.Coffee, M.Nishino, A.P.Cogdill, R.D.Brown, P.Della Pelle, D.Dias-Santagata, K.E.Hung, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2:227–35; PMID:22448344; http://dx.doi.org/10.1158/2159-8290.CD-11-0341
7. G.Bollag, J.Tsai, J.Zhang, C.Zhang, P.Ibrahim, K.Nolop, P.Hirth. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov 2012; 11:873–86; PMID:23060265; http://dx.doi.org/10.1038/nrd3847
8. P.I.Poulikakos, C.Zhang, G.Bollag, K.M.Shokat, N.Rosen. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010; 464:427–30; PMID:20179705; http://dx.doi.org/10.1038/nature08902
9. A.Prahallad, C.Sun, S.Huang, F.Di Nicolantonio, R.Salazar, D.Zecchin, R.L.Beijersbergen, A.Bardelli, R.Bernards. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483:100–3; PMID:22281684; http://dx.doi.org/10.1038/nature10868
10. F.Su, W.D.Bradley, Q.Wang, H.Yang, L.Xu, B.Higgins, K.Kolinsky, K.Packman, M.J.Kim, K.Trunzer, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2012; 72:969–78; PMID:22205714; http://dx.doi.org/10.1158/0008-5472.CAN-11-1875
11. R.Nazarian, H.Shi, Q.Wang, X.Kong, R.C.Koya, H.Lee, Z.Chen, M.K.Lee, N.Attar, H.Sazegar, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973–7; PMID:21107323; http://dx.doi.org/10.1038/nature09626
12. H.Shi, W.Hugo, X.Kong, A.Hong, R.C.Koya, G.Moriceau, T.Chodon, R.Guo, D.B.Johnson, K.B.Dahlman, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014; 4:80–93; PMID:24265155; http://dx.doi.org/10.1158/2159-8290.CD-13-0642
13. H.Shi, X.Kong, A.Ribas, R.S.Lo. Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 2011; 71:5067–74; PMID:21803746; http://dx.doi.org/10.1158/0008-5472.CAN-11-0140
14. S.D.J.Kopetz, E.Chan, J.R.Hecht, P.J.O'Dwyer, R.J.Lee, et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 2010; (suppl) 28:15s (abstract nr 3534); PMID:19933920; http://meetinglibrary.asco.org/content/50595-74
15. D.M.J.Planchard, G.J.Riely, C.M.Rudin, F.Barlesi, et al. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2013; 31(suppl):(abstr 8009); PMID:23669222; http://meetinglibrary.asco.org/content/112427-132
16. P.Lito, N.Rosen, D.B.Solit. Tumor adaptation and resistance to RAF inhibitors. Nat Med 2013; 19:1401–9; PMID:24202393; http://dx.doi.org/10.1038/nm.3392
17. G.Hatzivassiliou, K.Song, I.Yen, B.J.Brandhuber, D.J.Anderson, R.Alvarado, M.J.Ludlam, D.Stokoe, S.L.Gloor, G.Vigers, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464:431–5; PMID:20130576; http://dx.doi.org/10.1038/nature08833
18. S.J.Heidorn, C.Milagre, S.Whittaker, A.Nourry, I.Niculescu-Duvas, N.Dhomen, J.Hussain, J.S.Reis-Filho, C.J.Springer, C.Pritchard, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140:209–21; PMID:20141835; http://dx.doi.org/10.1016/j.cell.2009.12.040
19. M.J.Garnett, S.Rana, H.Paterson, D.Barford, R.Marais. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005; 20:963–9; PMID:16364920; http://dx.doi.org/10.1016/j.molcel.2005.10.022
20. P.T.Wan, M.J.Garnett, S.M.Roe, S.Lee, D.Niculescu-Duvaz, V.M.Good, C.M.Jones, C.J.Marshall, C.J.Springer, D.Barford, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116:855–67; PMID:15035987; http://dx.doi.org/10.1016/S0092-8674(04)00215-6
21. M.Holderfield, H.Merritt, J.Chan, M.Wallroth, L.Tandeske, H.Zhai, J.Tellew, S.Hardy, M.Hekmat-Nejad, D.D.Stuart, et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell 2013; 23:594–602; PMID:23680146; http://dx.doi.org/10.1016/j.ccr.2013.03.033
22. A.M.Menzies, R.F.Kefford, G.V.Long. Paradoxical oncogenesis: are all BRAF inhibitors equal?. Pigment Cell Melanoma Res 2013; 26:611–5; PMID:23795808; http://dx.doi.org/10.1111/pcmr.12132
23. K.T.Flaherty, J.R.Infante, A.Daud, R.Gonzalez, R.F.Kefford, J.Sosman, O.Hamid, L.Schuchter, J.Cebon, N.Ibrahim, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367:1694–703; PMID:23020132; http://dx.doi.org/10.1056/NEJMoa1210093